Chávez GE, Romero RN, Pardo MRV

Language: Spanish
References: 11
Page: 73-76
PDF size: 41.67 Kb.

ABSTRACT

Introduction: In recent decades, mortality rates from heart disease have shown a steady increase, up to become the leading cause of death in Mexico. A similar situation occurred with the cerebro-vascular disease, which ranks sixth in overall mortality. It is well known protective effect of estrogen in women and increased risk of cerebrovascular disease in post-menopausal period. Objective: To demonstrate the protective effect of estrogen on lipid metabolism. Material and methods: An observational, retro-prospective, cross-sectional study included patients in the pre and postmenopausal at the Hospital of Gynecology and Obstetrics IMIEM. Results: We included 173 patients with a mean age of 47.1 years (minimum 36 and maximum 69 years), of which 55 patients (38.1%) were premenopausal and 118 patients (68.2%) in post-menopausal period. Castelli Index was calculate (total cholesterol/HDL cholesterol) as a predictor of cardiovascular risk an found that 70.9% (n = 39) of premenopausal patients were at low risk compared with 9.3% (n = 11) of patients post-menopausal. In contrast to the high risk in which 22% (n = 26) of postmenopausal patients and only 1.8% (n = 1) in premenopausal period. Correlation was used to observe the Pearson r relationship between menopause and the rate of Castelli. The results show a positive correlation of 0.636 with a significance level of p = 0.001. Conclusion: There is a strong correlation between the rate of Castelli and age of the patients.

REFERENCES

1. Rocabado UEJ, Rocha SMI, Rivera RCM y cols. Síndrome metabólico en la menopausia, Rev Méd (Cochabamba), 2007; 18 (28): 85-90.

2. Lobo RA. Síndrome metabólico después de la menopausia y el papel de las hormonas, Rev Climaterio, 2009; 13 (73): 1-10.

3. Pisabarro R. Metabolismo y climaterio: La visión de un endocrinólogo, Rev Med Uruguay, 2000; 16: 144-151.

4. Pilnik S, Figueroa CP. Síndrome metabólico y menopausia: fisiopatología, diagnóstico y prevención, Rev Endocrinol Ginec Reprod, 2002; 5: 357-365.

5. Kaaja RJ. Metabolic syndrome and the menopause, Menopause Int, 2008; 14: 21-25.

6. Thoot MJ, Sites CK, Eltabaakh EG, Poehlman ET. Effect of menopausal status on insulin-stimulated glucose disposal comparison of middle-aged premenopausal and early postmenopausal women, Diabetes Care, 2000; 23: 801-806.

7. Orgaz MMT, Hijano VS, Martínez LMS, López BJ, Díaz PJ. Guía del paciente con trastornos lipídicos. Ministerio de Sanidad y Consumo, Instituto de Gestión Sanitaria. Madrid, 2007, En: http://www.ingesa.msc.es/estadEstudios/documPublica/internet/pdf/guiaTrastornosLipidicos.pdf

8. Arellano O, Barquea S, Barriguete JA, Lara EA, López PA, Rosas M. Protocolo clínico para el diagnóstico y tratamiento de las dislipidemias, Secretaría de Salud. México 2008, En: http://www.jalisco.gob.mx/wps/wcm/connect/fe826b804f34634cae19ae4a32ff0230/protocolo_dislipidemias.pdf?MOD=AJPERES

9. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab, 2003; 88: 2404-2411.

10. Norma Oficial Mexicana NOM-037-SSA-2002, Para la prevención, tratamiento y control de las dislipidemias.

11. Castelli WP. Epidemiology of coronary heart disease: The Framingham Study, Am J Med, 1984; 76: 4-9.